TY - JOUR
T1 - Meloxicam Inhibit the Growth of Oral Squamous Cell Carcinoma Induced by Benzopyrenes
AU - Arundina, Ira
AU - Budhy, Theresia Indah
AU - Surboyo, Meircurius Dwi Condro
N1 - Publisher Copyright:
© 2020 UPM Press. All rights reserved.
PY - 2020/7
Y1 - 2020/7
N2 - Introduction: Meloxicam is a NSAID which able to inhibit the cyclooxygenase 2 (COX-2). The purpose of this research is to explain the effect of Meloxicam in inhibit the growth of oral squamous cell carcinoma (OSCC) induced by benzopyrenes. The apoptosis and proliferation of OSCC, the p53, Ras and COX-2 expression used as indicator. Methods: male mice were induced by benzopyrene 10 mg/kg body weight was given topically on buccal mucosa 2 times a week for 4 weeks for induced the OSCC. Meloxicam was given orally with 3 different doses was 50mg/kg, 100mg/kg, and 200mg/kg.b.w given once a day for 60 days. The control groups were given with CMC-1% 0.1ml/10g body weight. The buccal mucosa then biopsy and staining with immunohistochemistry to analyzed the p53, Ras, COX-2 expression, apoptosis and proliferation of OSCC. Results: The increase of Meloxicam dose is proportional to the increase in wild p53 expression and apoptosis, and inversely proportional to the expression of mutant race, cox-2 and the proliferation of OSCC. Conclusion: Meloxicam able to inhibit the growth of OSCC induced by benzopyrenes.
AB - Introduction: Meloxicam is a NSAID which able to inhibit the cyclooxygenase 2 (COX-2). The purpose of this research is to explain the effect of Meloxicam in inhibit the growth of oral squamous cell carcinoma (OSCC) induced by benzopyrenes. The apoptosis and proliferation of OSCC, the p53, Ras and COX-2 expression used as indicator. Methods: male mice were induced by benzopyrene 10 mg/kg body weight was given topically on buccal mucosa 2 times a week for 4 weeks for induced the OSCC. Meloxicam was given orally with 3 different doses was 50mg/kg, 100mg/kg, and 200mg/kg.b.w given once a day for 60 days. The control groups were given with CMC-1% 0.1ml/10g body weight. The buccal mucosa then biopsy and staining with immunohistochemistry to analyzed the p53, Ras, COX-2 expression, apoptosis and proliferation of OSCC. Results: The increase of Meloxicam dose is proportional to the increase in wild p53 expression and apoptosis, and inversely proportional to the expression of mutant race, cox-2 and the proliferation of OSCC. Conclusion: Meloxicam able to inhibit the growth of OSCC induced by benzopyrenes.
KW - Benzopyrene
KW - Meloxicam
KW - Oral squamous cells carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85090584342&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85090584342
SN - 1675-8544
VL - 16
SP - 22
EP - 25
JO - Malaysian Journal of Medicine and Health Sciences
JF - Malaysian Journal of Medicine and Health Sciences
IS - S4
ER -